STOCK TITAN

Janux Therapeutics (JANX) awards director RSUs and 15,500 options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Janux Therapeutics director Eric Dobmeier received new equity awards. He was granted 5,500 restricted stock units, each representing one share of common stock, which will vest on the earlier of June 11, 2027 or the next annual stockholder meeting, subject to continued service.

He was also granted options to buy 15,500 shares of common stock at an exercise price of $13.66 per share, expiring on June 10, 2036. These options vest in equal monthly installments over the 12 months following June 11, 2026 and will in any case be fully vested by the next annual stockholder meeting, subject to continued service. Following these grants, he directly holds 15,481 common shares.

Positive

  • None.

Negative

  • None.
Insider DOBMEIER ERIC
Role null
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 15,500 $0.00 --
Grant/Award Common Stock 5,500 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 15,500 shares (Direct, null); Common Stock — 15,481 shares (Direct, null)
Footnotes (1)
  1. Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 11, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date. The shares subject to the option will vest in equal monthly installments over the 12 months following June 11, 2026, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date.
RSU grant 5,500 shares Restricted stock units granted to director on June 11, 2026
Option grant size 15,500 shares Stock options granted on June 11, 2026
Option exercise price $13.66 per share Strike price for 15,500 stock options
Option expiration June 10, 2036 Expiration date of stock options
Common shares held 15,481 shares Direct common stock holdings after grants
RSU vesting date June 11, 2027 Latest vesting date, or earlier at next annual meeting
Option vesting period 12 months Equal monthly vesting after June 11, 2026
restricted stock units ("RSUs") financial
"Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Stock Option (right to buy) financial
"security_title": "Stock Option (right to buy)""
vest financial
"The RSUs will vest on the earlier of (i) June 11, 2027 and (ii) the date of the next annual meeting"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
annual meeting of the Issuer's stockholders financial
"the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service"
exercise price financial
"conversion_or_exercise_price": "13.6600""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
DOBMEIER ERIC

(Last)(First)(Middle)
C/O JANUX THERAPEUTICS, INC.
10955 VISTA SORRENTO PARKWAY, SUITE 200

(Street)
SAN DIEGO CALIFORNIA 92130

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Janux Therapeutics, Inc. [ JANX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/11/2026A5,500(1)A$015,481D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$13.6606/11/2026A15,500 (2)06/10/2036Common Stock15,500$015,500D
Explanation of Responses:
1. Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 11, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date.
2. The shares subject to the option will vest in equal monthly installments over the 12 months following June 11, 2026, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date.
/s/ James Pennington, Attorney-in-Fact06/12/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Janux Therapeutics (JANX) director Eric Dobmeier receive in this Form 4?

Eric Dobmeier received equity compensation consisting of 5,500 restricted stock units and options for 15,500 shares. These awards are part of his director compensation and are subject to multi-year and meeting-based vesting conditions tied to his continued board service.

How do the 5,500 RSUs granted to JANX director Eric Dobmeier vest?

The 5,500 RSUs vest on the earlier of June 11, 2027 or the date of Janux Therapeutics’ next annual stockholder meeting. Vesting is contingent on Dobmeier’s continuous service as of the applicable date, aligning his incentives with the company’s long-term performance.

What are the key terms of Eric Dobmeier’s 15,500 JANX stock options?

Dobmeier’s options cover 15,500 shares of Janux common stock with a $13.66 exercise price and a June 10, 2036 expiration. They vest in equal monthly installments over 12 months after June 11, 2026, or fully by the next annual meeting, subject to continued service.

Is this JANX Form 4 a market purchase or sale of shares?

This Form 4 reflects compensation-related grants, not open-market trades. Dobmeier received RSUs and stock options at no cash cost per share, with vesting tied to future service, rather than buying or selling shares on the open market for investment purposes.

How many Janux Therapeutics shares does Eric Dobmeier own after these grants?

Following the equity awards, Dobmeier directly holds 15,481 shares of Janux common stock. This figure reflects his post-transaction common share position and sits alongside his newly granted 5,500 RSUs and 15,500 stock options that vest over time.